IMC Logo.jpg
Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile
April 11, 2019 10:00 ET | Immuron Limited
C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues...
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé
January 31, 2019 02:00 ET | Deinove
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé Le design de l’essai a été optimisé pour maximiser les chances de démontrer...
logo.jpg
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner
January 31, 2019 02:00 ET | Deinove
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner The test design has been improved for a better assessment of DNV3837 effectiveness in...
IMC Logo.jpg
Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)
January 31, 2018 09:30 ET | Immuron Limited
Key Highlights: First patients enrolled in Immuron’s IMM-529 clinical study at Hadassah Medical Center in Israel Trial will treat 60 confirmed patients over 28 days to evaluate safety and efficacy of...
TOMI.jpg
SteraMist™ Contributes to Substantial Reduction in Clostridium Difficile Burden in Hospital
April 03, 2017 16:05 ET | TOMI Environmental Solutions, Inc.
BEVERLY HILLS, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination and infection prevention company that specializes in...
Paratek Pharmaceuticals Logo
Paratek Presents Pre-Clinical Data on the Effects of Omadacycline on Clostridium Difficile
April 11, 2016 07:30 ET | Paratek Pharmaceuticals
AMSTERDAM, Netherlands, April 11, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today presented data from two pre-clinical studies evaluating the impact of omadacycline on...
Paratek Pharmaceuticals Logo
Paratek Presents Data from Omadacycline Clinical Development Program at ECCMID
April 11, 2016 07:30 ET | Paratek Pharmaceuticals
Pooled analysis from Phase 2 and truncated Phase 3 studies demonstrates comparable safety and efficacy profiles for omadacycline compared with linezolid  Single dose randomized trial...
C. difficile Infection Increases Hospital Costs by 40 Percent Per Case, Study Finds
December 10, 2015 09:27 ET | Premier, Inc.
Patients with C. diff stay in hospital 55 percent longer and are 77 percent more likely to be readmitted CHARLOTTE, N.C., Dec. 10, 2015 (GLOBE NEWSWIRE) --  Clostridium difficile (C. diff),...
OpenBiome logo
Fecal transplant pills: Large-scale production begins
October 28, 2015 08:39 ET | OpenBiome
BOSTON, Oct. 28, 2015 (GLOBE NEWSWIRE) -- A new pill created by a team of MIT-trained researchers provides fecal transplant therapy without requiring the traditional, more invasive stool delivery...
Stellar Biotechnologies to Present at the 26th Annual ROTH Capital Growth Conference
February 27, 2014 09:05 ET | Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwired - Feb 27, 2014) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), a company focused in the immunotherapy arena with...